Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vaccination With Autologous Dendritic Cells Pulsed With Tumor Lysate for Treatment of Patients With Malignant Pleural Mesothelioma.

Next Previous
X
Search
Trial Profile

Vaccination With Autologous Dendritic Cells Pulsed With Tumor Lysate for Treatment of Patients With Malignant Pleural Mesothelioma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary)
  • Indications Malignant-mesothelioma
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Jun 2021 Results of a pooled analysis assessing the long-term survival of the patients treated with dendritic cell in these three phase 1 studies presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Planned end date changed from 31 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top